09:56 AM EST, 12/20/2024 (MT Newswires) -- Merit Medical Systems ( MMSI ) said Friday that the US Food and Drug Administration granted premarket approval to the company's Wrapsody cell-impermeable endoprosthesis.

With the approval, the healthcare technology company said it will be able to begin selling the device in the USA in 2025.

The device is designed to improve long-term vessel patency in dialysis patients by addressing complications such as stenosis and thrombosis in arteriovenous fistulas or grafts, critical for maintaining adequate blood flow and patient survival during dialysis, Merit Medical ( MMSI ) said.

Merit Medical ( MMSI ) shares rose 2.1% in early trading.

Price: 98.28, Change: +2.01, Percent Change: +2.08